journal article·2026-01-12Open access

Nitric Oxide-Releasing Thixotropic Hydrogels as Antibacterial and Hemocompatible Catheter Locks

Wuwei Li, Loren Liebrecht, Surendra Poudel, Rebecca Goodhart, Sayaji More, Jade Montano, Derek Lust, Qingguo Xu, Martin Mangino, Xuewei Wang

Abstract

Catheters are indispensable medical tools for accessing blood vessels, hollow organs, and body cavities to facilitate medication delivery and fluid drainage. However, they also serve as major entry points for bacterial contamination and trigger foreign body responses, necessitating locking strategies that are both bactericidal and biocompatible. This study introduces the first gel-based catheter lock, in contrast to conventional liquid locks. The gel is a poloxamer-based hydrogel formulated with 2-hydroxypropyl α-cyclodextrin (HP-αCD). HP-αCD forms supramolecular complexes with the poloxamer to enhance gelation and with the nitric oxide (NO) donor to modulate NO release kinetics. This thixotropic gel can be injected into the catheter lumen when the catheter is not in use and withdrawn when vascular access is needed. The gel matrix provides a physical barrier that slows bacterial migration and minimizes drug loss. Simultaneously, the released NO functions as a broad-spectrum antimicrobial agent, effectively preventing biofilm formation on both the internal and external surfaces of the catheter. The NO-releasing hydrogel also demonstrates excellent hemocompatibility and reduces clot adhesion. Together, the gel-based lock offers a promising strategy for more effective catheter maintenance and represents a new application of hydrogels.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Polymer Surface Interaction Studies · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry

Virginia Commonwealth University

Department of Surgery

Department of Pharmaceutics

Funding

National Heart, Lung, and Blood Institute · Virginia Commonwealth University

References (74)

Show source-provided references
1. 10.1259/bjr.2022089410.1259/bjr.20220894 ↗
2. 10.1080/0886022X.2022.211806810.1080/0886022X.2022.2118068 ↗
3. Beathard, G. Malfunction of chronic hemodialysis catheters - UpToDate . 2025. https://www.uptodate.com/contents/malfunction-of-chronic-hemodialysis-catheters.
4. CDC. Surveillance Summary of Bloodstream Infections in Outpatient Hemodialysis Facilities ─ National Healthcare Safety Network, 2014–2019 . 2014. https://www.cdc.gov/dialysis-safety/media/pdfs/BSI-NHSN-2014to2019-508.pdf.
5. 10.1371/journal.pone.015134810.1371/journal.pone.0151348 ↗
6. CDC. Background Information: Strategies for Prevention of Catheter-Related Infections in Adult and Pediatric Patients . 2011. https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/prevention-strategies.
7. 10.1080/08927014.2011.59326110.1080/08927014.2011.593261 ↗
8. 10.1002/msj.2021310.1002/msj.20213 ↗
9. 10.1111/j.1525-139X.2011.00991.x10.1111/j.1525-139X.2011.00991.x ↗
10. 10.2147/IDR.S5138810.2147/IDR.S51388 ↗
11. FDA. FDA approves new drug under special pathway for patients receiving hemodialysis . 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-under-special-pathway-patients-receiving-hemodialysis.
12. 10.5301/jva.500068110.5301/jva.5000681 ↗
13. 10.1038/ki.2010.33210.1038/ki.2010.332 ↗
14. 10.1111/j.1525-139X.2007.00284.x10.1111/j.1525-139X.2007.00284.x ↗
15. 10.1097/01.MAT.0000094040.54794.2D10.1097/01.MAT.0000094040.54794.2D ↗
16. 10.1093/ndt/16.10.207210.1093/ndt/16.10.2072 ↗
17. 10.1093/ndt/gfn69610.1093/ndt/gfn696 ↗
18. 10.1086/60616210.1086/606162 ↗
19. 10.1155/2015/98568610.1155/2015/985686 ↗
20. 10.1097/01.MAT.0000159742.15560.9310.1097/01.MAT.0000159742.15560.93 ↗
21. 10.3390/pharmaceutics1303035710.3390/pharmaceutics13030357 ↗
22. 10.3390/gels805030110.3390/gels8050301 ↗
23. 10.1021/acs.chemrev.2c0017910.1021/acs.chemrev.2c00179 ↗
24. 10.1007/0-306-46816-6_1210.1007/0-306-46816-6_12 ↗
25. 10.1093/clinids/21.Supplement_2.S16210.1093/clinids/21.Supplement_2.S162 ↗
26. 10.1016/S0021-9258(17)30619-110.1016/S0021-9258(17)30619-1 ↗
27. 10.1039/C6BM00271D10.1039/C6BM00271D ↗
28. 10.1039/D1TB00847A10.1039/D1TB00847A ↗
29. 10.1021/acsabm.1c0127210.1021/acsabm.1c01272 ↗
30. 10.1021/acsbiomaterials.2c0128410.1021/acsbiomaterials.2c01284 ↗
31. 10.1021/acsami.3c0250610.1021/acsami.3c02506 ↗
32. 10.1039/D3BM00775H10.1039/D3BM00775H ↗
33. 10.1021/acsami.1c0642710.1021/acsami.1c06427 ↗
34. 10.1128/JCM.39.6.2294-2297.200110.1128/JCM.39.6.2294-2297.2001 ↗
35. 10.1016/j.cocis.2023.10170410.1016/j.cocis.2023.101704 ↗
36. 10.3390/pharmaceutics1407137710.3390/pharmaceutics14071377 ↗
37. 10.1002/advs.20170104310.1002/advs.201701043 ↗
38. 10.1016/j.ijbiomac.2023.12637110.1016/j.ijbiomac.2023.126371 ↗
39. 10.1002/admt.20220152910.1002/admt.202201529 ↗
40. 10.1021/acsami.5c0325010.1021/acsami.5c03250 ↗
41. 10.1089/ten.teb.2021.002610.1089/ten.teb.2021.0026 ↗
42. 10.2147/IJN.S41853410.2147/IJN.S418534 ↗
43. 10.1016/j.actbio.2018.05.02510.1016/j.actbio.2018.05.025 ↗
44. 10.1007/s10856-013-4973-710.1007/s10856-013-4973-7 ↗
45. 10.1016/j.colsurfb.2015.04.00710.1016/j.colsurfb.2015.04.007 ↗
46. 10.3390/pharmaceutics1210092610.3390/pharmaceutics12100926 ↗
47. 10.1016/j.jddst.2017.10.01610.1016/j.jddst.2017.10.016 ↗
48. 10.1016/j.jss.2007.10.01510.1016/j.jss.2007.10.015 ↗
49. 10.1111/j.1468-3083.2006.02032.x10.1111/j.1468-3083.2006.02032.x ↗
50. 10.1002/mame.20240034110.1002/mame.202400341 ↗
51. 10.1021/ma010742s10.1021/ma010742s ↗
52. 10.1039/D0SM00979B10.1039/D0SM00979B ↗
53. 10.1159/00012370610.1159/000123706 ↗
54. 10.1111/hdi.2000.4.1.2210.1111/hdi.2000.4.1.22 ↗
55. 10.1053/j.ajkd.2019.12.00110.1053/j.ajkd.2019.12.001 ↗
56. 10.1016/j.jconrel.2015.04.03210.1016/j.jconrel.2015.04.032 ↗
57. 10.1016/j.bbagen.2013.02.00410.1016/j.bbagen.2013.02.004 ↗
58. 10.1126/scitranslmed.aah553310.1126/scitranslmed.aah5533 ↗
59. 10.1016/j.biomaterials.2013.07.04510.1016/j.biomaterials.2013.07.045 ↗
60. 10.1016/S0142-9612(00)00153-810.1016/S0142-9612(00)00153-8 ↗
61. 10.1016/j.actbio.2005.07.01010.1016/j.actbio.2005.07.010 ↗
62. 10.1007/s13239-011-0040-z10.1007/s13239-011-0040-z ↗
63. 10.1016/j.mechmat.2022.10452010.1016/j.mechmat.2022.104520 ↗
64. 10.1093/ndt/gfh55010.1093/ndt/gfh550 ↗
65. 10.1038/ki.2010.47110.1038/ki.2010.471 ↗
66. National Kidney Foundation. Catheter-Related Bloodstream Infection (CRBSI) . 2024. https://www.kidney.org/kidney-topics/catheter-related-bloodstream-infection-crbsi.
67. 10.12968/bjon.2023.32.Sup7.S410.12968/bjon.2023.32.Sup7.S4 ↗
68. 10.12968/bjon.2023.32.19.S2010.12968/bjon.2023.32.19.S20 ↗
69. 10.1016/j.niox.2019.05.00910.1016/j.niox.2019.05.009 ↗
70. 10.1021/acsami.0c1323010.1021/acsami.0c13230 ↗
71. 10.3390/pharmaceutics1309144510.3390/pharmaceutics13091445 ↗
72. 10.1002/adhm.20180015510.1002/adhm.201800155 ↗
73. 10.1021/bi501476n10.1021/bi501476n ↗
74. CDC. Guidelines for the Prevention of Intravascular Catheter-Related Infections . 2011. https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/index.html.